Drug labeling initiative BPA

Active Blanket Purchase Agreement Awarded Last action

Contract number
75F40122A00018
Awardee
Awarding agency
Task orders
12 $29,860,608 obligated

Award facts

Combined order value
  • $29,860,608 Current, with exercised options
  • $38,305,684 Potential, with all options
Last date to order 81% complete
IDV ceiling 97% used
$30,813,738.04
Award type
Single award
Who can order
Only the awarding agency
Set-aside
No set-aside
Pricing
Order Dependent (IDV only)

Award details come from SAM.gov/FPDS.

About this IDV

Written by GovTribe AI ·

The Food and Drug Administration awarded a single-award Blanket Purchase Agreement valued at $30.8 million to Deloitte Consulting LLP, effective September 28, 2022 through September 29, 2027, to support the Drug Labeling Initiative. This civilian agency contract, issued without small business set-asides, establishes a framework for delivering consulting and regulatory support services related to drug labeling processes and compliance. Deloitte, headquartered in Arlington, Virginia, brings extensive expertise in data analytics, program management, and strategic consulting to support the FDA's mission-critical regulatory functions. The contract structure allows the FDA to issue task orders and call orders against the blanket purchase agreement ceiling as requirements emerge, enabling flexible procurement of professional services without requiring full recompetition for each engagement.

Under this indefinite delivery vehicle, the FDA has issued multiple call orders totaling approximately $6.4 million through December 2026, with documented task orders supporting the Office of Chief Economist continuity operations, drug labeling updates for older pharmaceutical products, and regulatory compliance initiatives. Work is being performed across multiple locations including Arlington and Silver Spring, Maryland (FDA headquarters), and Beltsville, Maryland. The individual task orders employ firm fixed-price pricing structures and range from approximately $163,000 to $1.81 million in value, with performance periods extending from mid-2023 through late 2026. These deliverables support the FDA's efforts to enhance and modernize drug labeling processes, ensuring regulatory compliance and public health protection through updated pharmaceutical product information and related administrative support services.

Task orders

Task order Ordering agency Obligated Awarded
Modern labeling act implementation 75F40126F19010 Food and Drug Administration $1,520,878
Device extensions (DEX) production scaling 75F40126F19013 Food and Drug Administration $1,496,602
Drug labeling initiative - cder support 75F40126F19012 Food and Drug Administration $5,692,682
EO 14398 75F40126F19011 Food and Drug Administration $11,316,218
EO 14398-firm-fixed-price BPA call under BPA 75F40122A00018 to provide research, analytical, labeling strategy… 75F40126F19009 Food and Drug Administration $1,426,532
BPA call order against 75F40122A00018 "drug labeling initiative BPA" to provide the OCE continuity support 75F40126F19008 Food and Drug Administration $1,809,344
Drug labeling initiative BPA 75F40125F19007 Food and Drug Administration $1,747,919
OCE drug labeling 75F40124F19006 Food and Drug Administration $163,085
Deloitte drug labeling 75F40124F19005 Food and Drug Administration $1,520,197
This is a firm fixed price (FFP) task order to acquirer drug labeling initiative. 75F40123F19004 Food and Drug Administration $252,729
Drug labeling initiative - call order #2 services for updating labelling of older drugs 75F40123F19002 Food and Drug Administration $1,484,625
Drug labeling initiative - task order - services for updating labelling of older drugs 75F40122F19001 Food and Drug Administration $1,429,797
Show all 12

Transactions

Action Obligated Date
Exercise an Option P00004 $0
Exercise an Option P00003 $0
Exercise an Option P00002 $0
Exercise an Option P00001 $0
Original award $0

Subawards

Subcontractor Amount Awarded
Shabas Solutions LLC BPA call order against 75F40122A00018 "drug labeling initiative BPA" to provide the OCE continuity support BPA call order against 75F40122A00018 "drug… $69,465
Shabas Solutions LLC Drug labeling initiative BPA drug labeling initiative BPA $60,899

Quick answers

Who was awarded contract 75F40122A00018?

75F40122A00018 was awarded to Deloitte Consulting LLP by Food and Drug Administration (Department of Health and Human Services) on September 28, 2022.

How much is contract 75F40122A00018 worth?

Orders under 75F40122A00018 have obligated $29,860,608. Their combined potential value, with all options, is $38,305,684. 75F40122A00018's own ceiling is $30,813,738.

How many orders have been placed under contract 75F40122A00018?

12 orders have been placed under 75F40122A00018, the latest on September 30, 2026.

Who can order from contract 75F40122A00018?

75F40122A00018 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login